We are proud to present HL-ExoI, a low temperature exonuclease. HL-ExoI will enable treatment of sensitive samples, and inspire novel technology development. HL-ExoI acts specifically to degrade ssDNA in the 3’- to 5’ direction, producing 5’- mononucleotides as a byproduct.
Find out more about HL-ExoI.
ArcticZymes presents Glycerol-free dsDNase and Glycerol-free HL-dsDNase, two new members of the glycerol-free family of products. The dsDNases are well known products used for specific removal of dsDNA from a range of solutions, including commercial qPCR mastermixes and RNA solutions. The convenient, glycerol-free format makes these enzymes suitable for automatization and lyophilization.
View the product brochure.
ArcticZymes presents IsoPol™ DNA Polymerase, the first in a family of polymerases established to serve the genomic market segment. IsoPol™ DNA Polymerase is a low temperature polymerase, as opposed to PCR-related polymerases which are active at around 70ºC. Low temperature polymerases will enable novel technology development, serving markets that open up due to the increasing amount of available genetic information. The market for low temperature polymerases have been underserved, and ArcticZymes plans to provide a variety of low temperature polymerases to enable technology development for Gene Sequencing, Molecular Diagnostics and other markets.
Find out more about IsoPol™ DNA Polymerase.
ArcticZymes AS has received a Notice of Allowance for the United States Patent Application No. US9422595 covering patentable subject matter of its heat-labile Salt Active Nuclease (HL-SAN) product.
With the approval of the new patent in the USA, ArcticZymes strengthens its rapidly growing intellectual property portfolio. The patent extends protection in the USA to the nucleic acid sequence of its HL-SAN product. The enzyme is an endonuclease capable of operating at high salt concentrations. This opens up a wider utility for use of such enzymes.
“The HL-SAN portfolio has typically been utilized by our customers in the preparation of nucleic acid-free products such as recombinant proteins and reagents. More recently, it has attracted growing interest from manufacturers of adeno-associated virus (AAV) for utility in gene therapy. The new patent greatly strengthens our commercial efforts.” says Managing Director, Jethro Holter at ArcticZymes AS.